NeuroPhage to be Featured in Oral Session at the 2015 Alzheimer’s Association International Conference

Cambridge, Mass., July 13, 2015 – NeuroPhage Pharmaceuticals, Inc., today announced that Richard Fisher, PhD, the Company’s Chief Scientific Officer, will give an oral presentation at the Alzheimer’s Association International Conference, taking place July 18–23, 2015, in Washington D.C. Dr. Fisher will present scientific data and a clinical development plan update of the Company’s lead candidate, NPT088, which utilizes GAIM (General Amyloid Interaction Motif) technology to target multiple types of misfolded proteins found in many diseases of aging, such as Alzheimer’s and Parkinson’s diseases. His presentation, entitled “Discovery, Preclinical Development, and Clinical Trial Approach for NPT088, a General Amyloid Interaction Motif (GAIM)-Immunoglobulin Fusion,” will take place on Sunday, July 19 at 2:00 pm EDT.

About NeuroPhage

NeuroPhage Pharmaceuticals, Inc. is a privately funded company headquartered in Cambridge, Massachusetts. NeuroPhage’s mission is to advance the treatment of misfolded protein diseases through GAIM therapy, targeting multiple toxic misfolded proteins. NeuroPhage is initially developing drug candidates to treat Alzheimer’s and Parkinson’s diseases and several rare systemic amyloidosis diseases.


Media Contact
Sarah Sutton
Ten Bridge Communications
518-932-3680
sarah@tenbridgecommunications.com